These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 24619376)

  • 1. Kidney cancer: decreased incidence of skeletal-related events in mRCC.
    Yuasa T; Urakami S
    Nat Rev Urol; 2014 Apr; 11(4):193-4. PubMed ID: 24619376
    [No Abstract]   [Full Text] [Related]  

  • 2. The health care burden of skeletal related events in patients with renal cell carcinoma and bone metastasis.
    Antczak C; Trinh VQ; Sood A; Ravi P; Roghmann F; Trudeau V; Chang SL; Karakiewicz PI; Kibel AS; Krishna N; Nguyen PL; Saad F; Sammon JD; Sukumar S; Zorn KC; Sun M; Trinh QD
    J Urol; 2014 Jun; 191(6):1678-84. PubMed ID: 24384157
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacoeconomics of bisphosphonates for skeletal-related event prevention in metastatic non-breast solid tumours.
    Carter JA; Joshi AD; Kaura S; Botteman MF
    Pharmacoeconomics; 2012 May; 30(5):373-86. PubMed ID: 22500986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review.
    Gupta K; Miller JD; Li JZ; Russell MW; Charbonneau C
    Cancer Treat Rev; 2008 May; 34(3):193-205. PubMed ID: 18313224
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis on Inpatient Health Expenditures of Renal Cell Carcinoma in a Grade-A Tertiary Hospital in Beijing.
    Liu X; Mao YH; He XM; Zhang YJ; Sun Y
    Chin Med J (Engl); 2017 Oct; 130(20):2447-2452. PubMed ID: 29052566
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sunitinib First-line Treatment in Metastatic Renal Cell Carcinoma: Costs and Effects.
    Vuorinen RL; Paunu N; Turpeenniemi-Hujanen T; Reunamo T; Jekunen A; Kataja V; Sintonen H; Purmonen T; Kellokumpu-Lehtinen PL
    Anticancer Res; 2019 Oct; 39(10):5559-5564. PubMed ID: 31570450
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Health economic changes as a result of implementation of targeted therapy for metastatic renal cell carcinoma: national results from DARENCA study 2.
    Soerensen AV; Donskov F; Kjellberg J; Ibsen R; Hermann GG; Jensen NV; Fode K; Geertsen PF
    Eur Urol; 2015 Sep; 68(3):516-22. PubMed ID: 25533417
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economic burden of adverse events in patients with metastatic renal cell carcinoma.
    Hagiwara M; Borker R; Oster G
    Clin Ther; 2013 Dec; 35(12):1955-1963.e2. PubMed ID: 24290735
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacoeconomic and clinical implications of sequential therapy for metastatic renal cell carcinoma patients in Central and Eastern Europe.
    Vrdoljak E; Torday L; Szczylik C; Kharkevich G; Bavbek S; Sella A
    Expert Opin Pharmacother; 2016; 17(1):93-104. PubMed ID: 26619144
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ["... and now about the costs!"].
    Rohde D
    Aktuelle Urol; 2008 Jan; 39(1):2 p preceding table of contents. PubMed ID: 18303603
    [No Abstract]   [Full Text] [Related]  

  • 11. The Costly War Against Cancer Treatment: The Example of Metastatic Renal Cell Carcinoma in Portugal.
    Barata PC; Alpuim Costa D; Passos Coelho JL; Da Luz R
    Acta Med Port; 2018 Aug; 31(7-8):373-375. PubMed ID: 30189164
    [No Abstract]   [Full Text] [Related]  

  • 12. [Economic evaluation of targeted biologic therapy in metastatic renal cell carcinoma].
    Ondrácková B; Demlová R; Komínek J
    Klin Onkol; 2010; 23(6):439-45. PubMed ID: 21351422
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Authors Respond.
    Hansen RN; Hackshaw MD; Sullivan SD; Ramsey SD
    J Manag Care Spec Pharm; 2015 Sep; 21(9):844. PubMed ID: 26536677
    [No Abstract]   [Full Text] [Related]  

  • 14. The Authors Respond.
    Delea TE; Amdahl J; Diaz J; Nakhaipour HR; El Khoury MH
    J Manag Care Spec Pharm; 2015 Sep; 21(9):836-40. PubMed ID: 26536676
    [No Abstract]   [Full Text] [Related]  

  • 15. Optimizing treatment for patients with metastatic renal cell carcinoma in the Central and Eastern European region.
    Vrdoljak E; Ciuleanu T; Kharkevich G; Mardiak J; Mego M; Padrik P; Petruželka L; Purkalne G; Shparyk Y; Skrbinc B; Szczylik C; Torday L
    Expert Opin Pharmacother; 2012 Feb; 13(2):159-74. PubMed ID: 22195646
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current and predicted cost of metastatic renal cell carcinoma in Finland.
    Purmonen T; Nuttunen P; Vuorinen R; Pyrhönen S; Kataja V; Kellokumpu-Lehtinen P
    Acta Oncol; 2010 Aug; 49(6):837-43. PubMed ID: 20331406
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Welcome clinical leadership at NICE.
    Lancet; 2008 Aug; 372(9639):601. PubMed ID: 18722845
    [No Abstract]   [Full Text] [Related]  

  • 18. Costs associated with angiogenesis inhibitor therapies for metastatic renal cell carcinoma in clinical practice: results from a medical chart review study.
    Choueiri TK; McDermott D; Sheng Duh M; Sarda SP; Neary MP; Oh WK
    Urol Oncol; 2012; 30(6):848-55. PubMed ID: 20926319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Re: Health Economic Changes as a Result of Implementation of Targeted Therapy for Metastatic Renal Cell Carcinoma: National Results from DARENCA Study 2.
    Laguna MP
    J Urol; 2016 Mar; 195(3):608. PubMed ID: 26887702
    [No Abstract]   [Full Text] [Related]  

  • 20. The role of socioeconomic status in renal cell carcinoma.
    Hellenthal NJ; Bermejo CE
    Urol Oncol; 2012; 30(1):89-94. PubMed ID: 21908209
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.